Management Team

Khoso Baluch

Chief Executive Officer

Khoso Baluch was appointed Chief Executive Officer in October 2016. Mr. Baluch has built and led successful U.S. and international commercial teams in the primary care, specialty and hospital segments, launching leading products including Cialis, Byetta, Insulin devices, Cimzia, Vimpat and Neupro. During the 24 years Mr. Baluch worked for Eli Lilly & Co, he held international positions in general management, business development, market access and product leadership, and spanning Europe, the Middle East and the United States. At Lilly, as Diabetes Worldwide Franchise head, he had responsibility for guiding pipeline products from Phase 3 to completion on the market.  He oversaw a team of nearly 130 people responsible for the medical, regulatory, legal, supply chain, marketing, pricing and reimbursement aspects of drug launches in the U.S. and globally. Following his tenure at Lilly, Mr. Baluch held multiple positions at UCB, the global biopharmaceutical company, as Senior Vice President & Chief Marketing Officer and most recently serving as Senior Vice President & President European Middle East & Africa (EMEA) Region. Since 2013, Mr. Baluch has been a board member of Poxel, a French publically traded Biotech Company.

Antony E. Pfaffle, M.D.

Chief Scientific Officer and Co-Founder

Antony Pfaffle, M.D. has served as Chief Scientific Officer at CorMedix since January 1, 2013, and was a Director of CorMedix from 2007-2016. He was an Advisory Medical Director for ParagonRx, an Inventiv Company specializing in drug and device risk evaluation and mitigation. Dr. Pfaffle had been Director of Healthcare Research at Bearing Circle Capital, L.P., an investment fund, from May 2007 to July 2010. He was a Managing Director at Paramount BioCapital, Inc. and Senior Vice President of Business Development at Paramount BioSciences, LLC from December 2005 to May 2007. Dr. Pfaffle was a Principal and Founder of Black Diamond Research, an investment research company, from July 2001 to December 2005. Dr. Pfaffle is an internist who practiced nephrology at New York Hospital-Weill Cornell Medical Center, Lenox Hill Hospital and Memorial Sloan-Kettering Cancer Center. Dr. Pfaffle received his M.D. from New York Medical College.

Robert W. Cook

Chief Financial Officer

Robert Cook was appointed Chief Financial Officer in February 2017. Mr. Cook brings 25 years of international experience in senior financial leadership roles in the healthcare finance, pharmaceutical, and medical technology sectors, most recently serving as Chief Financial Officer of Bioblast Pharma Ltd. Prior to that, he held the position of Executive Vice President and Chief Financial Officer of Strata Skin Sciences a publicly-held medical technology company focused on the therapeutic and diagnostic dermatology market.  Mr. Cook’s prior pharma experience includes ten years as the CFO of Immune Pharmaceuticals and its predecessor EpiCept Corporation, including one year as Interim President and CEO of EpiCept in which he completed the reverse merger of EpiCept into Immune.  Prior to that he served six years as CFO at Pharmos Corporation.  Mr. Cook began his career in financial services at Chase Manhattan, including several years as a senior executive in its Hong Kong investment bank subsidiary, during which it lead-managed $8 billion in private and public debt financing for governments, public sector corporations and multinational enterprises. Additionally, he spent two years as a Vice President in the Healthcare Group at General Electric Capital Commercial Finance.  Mr. Cook holds a B.S. in Finance, magna cum laude, from The American University, in Washington, DC.

Judith R. Abrams, M.D., FRCPC

Chief Medical Officer

Judith Abrams, MD was appointed Chief Medical Officer in February 2017. Most recently, Dr. Abrams served as Head of Celgene Corporation’s Otezla (Apremilast) Global Clinical Submission Team where she led all clinical activities supporting the global submission through approval and launch of Otezla.  Previously, Dr. Abrams has held positions of increasing responsibility managing the clinical development of a portfolio of products across all phases of clinical development at Novo Nordisk, Inc. as Vice President, Medical & Science Inflammation,  NPS Pharmaceuticals, Inc. as Vice President of Clinical Development, Johnson & Johnson PRD as the Franchise Medical Leader for Reproductive Medicine, Urology, Anti-Infective, Wound Healing and Immunology, Inflammation & Pulmonary Global Drug Development, Novartis Pharmaceuticals Corporation as Head, Early Clinical Development for Arthritis, Bone Metabolism & Women’s Health, Amgen Inc., as Therapeutic Area Head, Bone & Joint Disease and Inflammation and Bristol-Myers Squibb PRI as Project Team Leader for Orencia (Abatacept).  Dr. Abrams received her MD. and completed fellowships in Internal Medicine and Rheumatology at the University of Toronto Faculty of Medicine.  She completed a post-doctoral research fellowship at Stanford University School of Medicine, Division of Immunology where she subsequently became a member of the clinical faculty.  Dr. Abrams is Adjunct Associate Professor, Department of Medicine, New York University School of Medicine. Dr. Abrams has won many awards and scholarships and has authored or co-authored numerous peer-reviewed publications.

John Ortiz

Vice President, Regulatory Affairs and Quality Assurance

John Ortiz joined CorMedix in January 2015. He has held executive positions in quality assurance/quality control and regulatory affairs at Johnson & Johnson’s domestic and international operations, Janssen Pharmaceutical, and Correvio LLC. In these roles, Mr. Ortiz oversaw the design of operations and quality control facilities, acquisition of innovative testing technologies, and quality management systems for pharmaceutical drugs and medical devices compliant with regulatory statutes and guidelines set by the U.S. Food and Drug Administration and EU Pharmaceutical Commission, and international operations in Asia Pacific and Latin America. He has also directed interdisciplinary teams and functions relating to the development of pharmaceutical products in diverse delivery systems, as well as the clinical and post-approval manufacturing and commercial distribution phases. Mr. Ortiz has more than 30 years of experience in the pharmaceutical industry.